<DOC>
	<DOCNO>NCT01326559</DOCNO>
	<brief_summary>Study Objective : Primary 1 . To evaluate complete response ( CR ) rate induction chemotherapy use Docetaxel , Cisplatin Fluorouracil ( TPF ) follow Docetaxel plus Cetuximab ( TC ) concurrence intensity-modulated radiotherapy ( IMRT ) . Secondary 1 . To determine overall response rate . 2 . To determine locoregional distant control rate 3 . To determine progression-free survival ( PFS ) 4 . To determine overall survival ( OS ) 5 . To determine safety induction chemotherapy concurrent chemoradiation plus Cetuximab .</brief_summary>
	<brief_title>Study Evaluate Induction Chemotherapy Using Docetaxel , Cisplatin Fluorouracil Concurrence With Intensity-modulated Radiotherapy Local Recurrent Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Recurrent T3N0N1M0 NPC ( AJCC/UICC 6th edition ) least 1 year end last primary course radiotherapy Age &gt; 18 &lt; 70 year Performance status : &lt; 1 ECOG System ( Appendix I ) Adequate bone marrow &amp; renal function Patients Bilirubin = &lt; 1.5 x ULN , ASAT &amp; ALST= &lt; 1.5 x ULN , Serum creatinine= &lt; 1.25 x ULN / Creatinine clearance &gt; = 60ml/min Patients WBC &gt; = 3x10e9/L , Neutrophils 1.8x10e9/L , Platelets &gt; = 100 x10e9/L , Hemoglobin &gt; =10g/dL Signed write informed consent Patients must least one measurable lesion Use investigational agent within past 28 day Pretreatment antiEGFR drug Severe cardiac disease heart failure , coronary artery disease myocardial infarction within last 12 month History severe pulmonary disease Active infection systemic disease poor control Uncontrolled chronic neuropathy Know grade 3 4 allergic reaction component treatment Estimated life expectancy le 3 month Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>induction chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>fluorouracil</keyword>
	<keyword>cetuximab</keyword>
	<keyword>intensity-modulated radiotherapy</keyword>
</DOC>